Rakuten Medical, a biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy platform, today announced that it has raised an additional $134 million in a second tranche of its Series C financing, bringing the total amount raised to $284 million. New investors include the SBI Group, Japan and Rakuten Inc…click here to continue reading